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Abstract: A low Omega-3 Index (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
in erythrocytes) is associated with cardiac, cerebral, and other health issues. Intake of EPA and DHA,
but not of alpha-linolenic acid (ALA), increases the Omega-3 Index. We investigated bioavailability,
safety, palatability and tolerability of EPA and DHA in a novel source: a variety of sausages.
We screened 96 healthy volunteers, and recruited 44 with an Omega-3 Index <5%. Participants
were randomly assigned to receive a variety of sausages enriched with approximately 250 mg EPA and
DHA per 80 g (n = 22) daily for 8 weeks, or matching placebo sausages (n = 22). All sausages contained
approximately 250 mg ALA/80 g. In the verum group, the mean Omega-3 Index increased from
4.18± 0.54 to 5.72± 0.66% (p < 0.001), while it remained unchanged in the placebo group. While ALA
levels increased only in the placebo group, DPA levels increased in both groups. Inter-individual
variability in the response was large. The mean increase of the Omega-3 Index per intake of EPA
and DHA we observed was higher than for other sources previously studied, indicating superior
bioavailability. As increasing production of EPA and DHA is difficult, improvements of bioavailability
can facilitate reaching the target range for the Omega-3 Index (8–11%).
Keywords: omega-3 index; omega-3 fatty acids; eicosapentaenoic acid; docosahexaenoic acid;
alpha-linolenic acid
1. Introduction
The two omega-3 fatty acids eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid
(DHA, 22:6n-3) fulfill important structural and functional roles in cell membranes [1,2]. Tissue levels of,
and thus the status of an individual in, EPA and DHA are represented by the Omega-3 Index, the sum
of EPA and DHA in erythrocytes, as analyzed with a highly standardized method [3]. A low Omega-3
Index is associated with elevated total and cardiovascular mortality [3,4], major depression [5,6],
impairments of cognitive function [7,8], and other health issues.
Theoretically, increasing intake of the plant-derived omega-3 fatty acid alpha-linolenic acid (ALA)
increases levels of EPA and DHA. However, conversion of ALA to EPA is poor, and ALA does not
increase DHA [9].
Increasing intake of EPA and DHA is the most effective way to increase the Omega-3 Index.
However, traditional sources of EPA and DHA have disappeared or are disappearing from our
diet. An example is the disappearance of DHA-containing cattle brain, due to the threat of bovine
spongiform encephalitis. Another is the reduction in the EPA and DHA content of farmed fish, due their
replacement by other fatty acids in fish farming. Therefore, novel food sources of EPA and DHA need
to be developed. One way is feeding EPA and DHA to animals to enrich their meat with both fatty
acids; another is by feeding alpha-linolenic acid to animals capable of converting alpha-linolenic acid
to EPA and DHA [10–18]. Clearly, these novel food products not only need to contain EPA and DHA,
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but EPA and DHA must also be bioavailable. Bioavailability is the extent to which a nutrient can
be absorbed and transported into systemic circulation or site of physiological activity. Bioavailability of
EPA and DHA varies with a number of factors, like specific emulsification, inter-individual differences,
concomitant food intake or chemical form [19]. This makes it imperative to demonstrate bioavailability
of EPA and DHA in any new food source. Moreover, the safety, tolerability and palatability of any new
food source needs to be documented.
The aim of the present study was to investigate how daily intake of a variety of sausages
supplemented with EPA and DHA (approximately 250 mg EPA and DHA and 240 mg ALA per day)
influences the Omega-3 Index, as compared to matching sausages supplemented only with ALA
(approximately 257 mg per day). Safety, tolerability, and palatability of the sausages were also assessed.
Finally, in a review of the pertinent literature, and using the change in Omega-3 Index per amount of
EPA and DHA ingested as a parameter, we compared the bioavailability we found, to the bioavailability
of other products.
2. Participants and Methods
2.1. Study Participants
From June until October 2014, healthy adults were asked to participate. Inclusion criteria
were (1) age (20–60 years); (2) willingness to eat 80 g/day of the sausage; (3) a low Omega-3 Index (<5%);
(4) adequate fluency in German or English to complete baseline and follow-up interviews; (5) stable
intake of food containing EPA and DHA before and during the study. Exclusion criteria were (1) regular
intake of omega-3 fatty acids supplements or >2 portions of fatty fish per week; (2) serious bleeding
disorder; (3) any acute and life-threatening condition; (4) significant medical co-morbidity; (5) seriously
limited life expectancy; (6) insulin-treated diabetes mellitus; (7) Body-Mass-Index (BMI) > 30 kg/m2;
(8) allergy, intolerance or history of hypersensitivity to components of study intervention; (9) pregnancy,
breast-feeding or childbearing potential without medically accepted method of contraception; (10) use
of any investigational agent within 30 days prior to screening visit; (11) known drug- or alcohol
abuse/dependence within the past 2 years. Only participants willing to adhere to all aspects of
the study protocol were recruited.
The study protocol was approved by the Ethics Committee of the Faculty of Medicine of
the Ludwig Maximilians-University of Munich and registered on Clinicaltrials.gov (NCT02148835).
All procedures were in accordance with current ethical standards of the Helsinki Declaration,
and the study was conducted according to Good Clinical Practice. Written informed consent
was obtained from all individuals before participating, allowing analysis of all clinical and laboratory
data mentioned in the present paper. The study was initiated, designed, conducted and evaluated
by the investigators, and the sponsor had no role in study design, data acquisition or evaluation,
or in preparation of the manuscript.
2.2. Study Design
The present study was a randomised, double-blind, placebo-controlled, mono-center comparison of
two matching groups of sausages (verum vs. placebo, Table 1). Randomisation was computer-generated.
Primary endpoint was a change in the Omega-3 Index. Secondary endpoints were safety, tolerability,
and palatability of the sausages, as assessed by a questionnaire including visual analogue scale (1 stands
for very poor and 10 for very good), and changes in blood lipids (cholesterol, high-density lipoprotein
cholesterol (HDL) and low-density lipoprotein cholesterol (LDL), total cholesterol, triglyceride), blood
glucose, HbA1c, liver enzymes (aspartate aminotransferase, alanine aminotransferase and g-glutamyl
transferase), creatinine, heart rate, blood pressure, BMI and WHR (waist to hip ratio) and changes
in the fatty acid composition of erythrocytes.
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Table 1. Amount of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in mg/80 g
(as eaten daily) of the investigational product.
Name of Sausage Amount of EPA + DHA (mg/80 g)
Bratwurst 408
Gourmet Trio 274
Leberkäse fein dick 296
Leberkäse fein dünn 296
Lyoner 280
Paprika Lyoner 280
Weißwurst 280
Wiener 296
The daily dosage of the investigational product of 80 g sausage was enriched with the amounts EPA and DHA
mentioned in Table 1 and 240 mg alpha-linolenic acid (ALA). The matching placebo product contained approximately
257 mg ALA per 80 g sausage. EPA and DHA were in the chemical form of an ethyl-ester, and produced from
Anchovis oil by KD Pharma, Bexbach, Germany. ALA was in the chemical form of a triglyceride, and produced
from rapeseed oil by Scheid AG, Überherrn, Germany.
After screening (t0) an 8-week intervention period followed. At run-in (t1) and at end-of-study
visit at week 8 (t8), blood samples and clinical parameters were obtained. Furthermore, participants
were asked about their food habits, especially about their fish intake or intake of omega-3 fatty acids.
Venous blood was collected by venipuncture at t0 in a non-fasting state to measure the Omega-3
Index, and at t1 and t8 after an overnight fast to measure predefined biochemical parameters as shown
in Table 2. At week 4 (t4), a telephone follow-up was conducted regarding palatability, adverse events,
compliance and changes of food habits. Study participants were requested to ingest 80 g/day of
sausages during the day at a time of their convenience and not to alter their current diet. Compliance
was assessed by interrogation.
Table 2. Clinical and biochemical parameters at baseline and end of study (Mean values ± standard
deviation).
Parameter Placebo(n = 22 *) t1
Verum
(n = 22 *) t1 p
Placebo
(n = 22) t8
Verum
(n = 22) t8 p
BMI (kg/m2) 23.47 ± 1.99 24.27 ± 2.71 0.269 23.60 ± 1.99 24.24 ± 2.76 0.379
WHR 0.78 ± 0.05 0.81 ± 0.09 0.120 0.77 ± 0.05 0.80 ± 0.08 0.127
HR (bpm) 67.0 ± 10.5 68.1 ± 11.6 0.745 70.3 ± 11.3 71.3 ± 11.7 0.770
BP Sys (mmHg) 127.1 ± 9.7 129.4 ± 13.3 0.516 130.3 ± 10.0 128.9 ± 14.9 0.728
BP Dia (mmHg) 75.9 ± 7.4 79.8 ± 10.0 0.143 76.2 ± 6.8 81.2 ± 10.5 0.068
Blood glucose (mg/dL) 86.4 ± 6.8 85.5 ± 4.9 0.646 84.0 ± 8.1 86.7 ± 10.6 0.345
HbA1c (%) 4.93 ± 0.21 4.92 ± 0.28 0.952 5.03 ± 0.25 5.04 ± 0.28 0.955
Total cholesterol (mg/dL) 162.6 ± 22.2 163.3 ± 33.4 0.941 165.3 ± 28.2 168.4 ± 37.2 0.754
HDL cholesterol (mg/dL) 60.7 ± 12.3 61.1 ± 9.9 0.904 59.7 ± 10.3 61.4 ± 11.6 0.623
LDL cholesterol (mg/dL) 90.6 ± 25.3 88.4 ± 30.0 0.787 91.7 ± 27.2 91.1 ± 32.3 0.944
Triglyceride (mg/dL) 72.3 ± 26.4 87.2 ± 35.4 0.122 87.0 ± 42.0 100.8 ± 55.8 0.360
Creatinine (mg/dL) 0.94 ± 0.12 0.94 ± 0.13 0.907 0.94 ± 0.11 0.93 ± 0.13 0.903
AST (U/L) 23.8 ± 5.5 29.3 ± 24.6 0.318 21.8 ± 4.5 23.2 ± 6.2 0.393
ALT (U/L) 25.1 ± 9.6 24.7 ± 9.8 0.889 22.5 ± 7.9 24.2 ± 11.1 0.544
GGT (U/L) 20.2 ± 10.1 28.3 ± 26.5 0.198 20.9 ± 10.8 26.5 ± 18.5 0.232
Omega-3 Index (%) 4.32 ± 0.35 4.18 ± 0.54 0.318 4.50 ± 0.51 5.72 ± 0.66 <0.001
BMI, body-mass-index; WHR, waist to hip ratio; HR, heart rate; BP Sys, systolic blood pressure; BP Dia, diastolic
blood pressure; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase. * At t1 values for AST, ALT
and GGT were only measured in 21 participants of the placebo group and values for blood glucose levels were only
measured in 21 participants in verum group.
The investigational product used was manufactured by Südbayerische Fleischwaren in Ingolstadt,
Germany. Outer packing of verum and placebo products looked identical. Participants were given
a variety of the products listed in Table 1. Participants were given 80 g packs for each day, which
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contained 500 kJ (120 kcal), 12 g protein, 0.8 g carbohydrates, 9 g total fat, of which 2.8 g were saturated
fatty acids, 4.5 g monounsaturated fatty acids, 1.4 g polyunsaturated fatty acids and 0.66 g sodium
(data supplied by the producer). All participants picked up a two-week supply of the experimental
sausages at the study center every two weeks in a refrigerated container. Care was taken that all
participants received an identical selection and amount of each of the sausages.
2.3. Laboratory Methods
Erythrocyte fatty acid composition was analysed according to the HS-Omega-3 Index®
methodology as previously described [20]. Other blood parameters were determined by the Department
of Clinical Chemistry—Klinikum Innenstadt (Ludwig-Maximilians-University, Munich, Germany)
using routine clinical chemistry methods.
2.4. Statistical Analyses
The power calculation was based on Köhler et al. [20], where 0.5 g EPA + DHA in the form
of a triglyceride in a convenience drink was given for 8 weeks, and the Omega-3 Index rose from
4.37 ± 0.51% to 6.8 ± 1.45%. Due to the lower dose (250 mg/day) and the form of an ethyl-ester
(at the time thought to be approximately 50% less bioavailable [21]), a fourth of the effect size within
8 weeks was anticipated, i.e., a change of +0.61%. The usual assumptions were made (alpha = 5%,
power = 80%). According to a web-based case estimate for this parallel-design study [22], the necessary
sample size was 44. The probability was 81% that the study would detect a treatment difference at
a one-sided 0.05 significance level, if the true difference between treatments was 0.580 units; standard
deviation of the response variable was assumed as 0.75. Analysis was by intention to treat.
Results are presented as means and standard deviations. Statistical differences were calculated
using an unpaired t-test for comparison of intervention versus control, and a paired t-test for
the comparison of baseline with end of the trial. Statistical differences in palatability and tolerability
were calculated using the Mann–Whitney U test to analyse variables of ordinal scale. Differences with
p values < 0.05 were considered statistically significant. Data were examined by IBM SPSS Statistics for
windows (release 18.0, IBM, Chicago, IL, USA).
2.5. Review of the Literature
A list of publications based on the HS-Omega-3 Index® is being continuously updated by one
of us (C.v.S.). This list, currently containing 219 entries, was searched for intervention trials, and
32 were found. Only trials with a continuous substitution of EPA and DHA, documented chemical
forms and dosages were selected. These trials were sorted according to the chemical form of EPA
and DHA used in the trial. Additional criteria excerpted were baseline Omega-3 Index in %, change
in Omega-3 Index in %, dose EPA + DHA given in mg/day, trial duration, and number of participants.
Change in Omega-3 Index in % per 100 mg EPA + DHA given per day in the respective trial was
calculated without correcting for trial duration. In a second step, the change in Omega-3 Index in % per
100 mg EPA + DHA given per day was related to trial duration and other factors possibly affecting
bioavailability, like chemical form, matrix used (e.g., liquid emulsion, fish oil, fish meal, krill oil, etc.).
3. Results
3.1. Screened Group
A total of 96 participants were screened; 44 were randomized. Main exclusion criterion (about 83%)
was an Omega-3 Index > 5.0%. Most of the individuals screened were university students, 60 male and
36 female, mean age 27.3± 7.2 years (female 28.6± 9.0 years, male 26.5± 5.8 years, p = 0.169) and mean
Omega-3 Index 4.93 ± 1.00% (female 5.13 ± 1.11%; male 4.80 ± 0.92%, p = 0.119). The distribution of
the Omega-3 Index among the screened participants is shown in Figure 1.
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3.3. Primary End Point
In the verum group, the daily intake of approximately 250 mg EPA and DHA as ethyl-esters
in a variety of sausages for 8 weeks increased the mean Omega-3 Index from 4.18 ± 0.54% to
5.72± 0.66% (p < 0.001, Table 3, Figure 3). Mean increase was 1.54± 0.75%, with a large inter-individual
variability (range 0.36–3.07%). The increase was independent of BMI (r = −0.09, p = 0.699) and age
(r = −0.40, p = 0.063), and there was no difference in response between female and male individuals
(p = 0.637).
Table 3. Fatty acid composition in erythrocytes at baseline and end of study—comparison between
verum and placebo groups at baseline (t0) and at 8 weeks (t8) respectively; (Mean values ± standard
deviation in %).
% of Total Fatty Acid Placebo(n = 22) t0
Verum
(n = 22) t0 p
Placebo
(n = 22) t8
Verum
(n = 22) t8 p
Omega-3 Index 4.32 ± 0.35 4.18 ± 0.54 0.318 4.50 ± 0.51 5.72 ± 0.66 <0.001
Omega-3 fatty acids
C22:6ω3 3.71 ± 0.40 3.64 ± 0.45 0.609 3.87 ± 0.45 4.75 ± 0.60 <0.001
C20:5ω3 0.61 ± 0.16 0.54 ± 0.18 0.175 0.63 ± 0.19 0.97 ± 0.27 <0.001
C18:3ω3 0.14 ± 0.04 0.17 ± 0.06 0.056 0.18 ± 0.08 0.15 ± 0.05 0.170
C22:5ω3 2.41 ± 0.47 2.43 ± 0.42 0.868 2.69 ± 0.44 2.69 ± 0.43 0.995
Omega-6 fatty acids
C20:4ω6 15.64 ± 1.59 15.40 ± 1.57 0.625 16.49 ± 1.35 15.54 ± 1.55 0.036
C18:2ω6 11.14 ± 1.98 10.86 ± 1.36 0.579 11.96 ± 1.46 11.33 ± 1.68 0.187
C18:3ω6 0.09 ± 0.06 0.08 ± 0.04 0.745 0.09 ± 0.03 0.07 ± 0.03 0.046
C20:2ω6 0.23 ± 0.05 0.24 ± 0.04 0.397 0.22 ± 0.04 0.21 ± 0.04 0.261
C20:3ω6 1.88 ± 0.41 1.93 ± 0.50 0.712 1.97 ± 0.36 1.82 ± 0.44 0.240
C22:4ω6 3.54 ± 0.60 3.52 ± 0.62 0.931 3.49 ± 0.68 3.14 ± 0.73 0.113
C22:5ω6 0.77 ± 0.19 0.80 ± 0.16 0.510 0.73 ± 0.16 0.64 ± 0.23 0.165
Saturated fatty acids
C14:0 0.46 ± 0.33 0.38 ± 0.09 0.299 0.30 ± 0.10 0.33 ± 0.11 0.268
C16:0 21.67 ± 0.96 21.83 ± 0.80 0.555 21.66 ± 1.11 22.44 ± 1.16 0.029
C18:0 18.39 ± 3.77 18.40 ± 3.81 0.987 16.27 ± 1.13 16.69 ± 2.82 0.526
C20:0 0.14 ± 0.05 0.14 ± 0.04 0.947 0.13 ± 0.03 0.13 ± 0.03 0.504
C22:0 0.26 ± 0.10 0.25 ± 0.09 0.708 0.40 ± 0.11 0.36 ± 0.10 0.187
C24:0 0.89 ± 0.46 0.73 ± 0.43 0.242 0.64 ± 0.28 0.64 ± 0.33 0.938
Cis-monounsaturated fatty acids
C16:1ω7 0.37 ± 0.16 0.58 ± 0.74 0.195 0.37 ± 0.17 0.41 ± 0.15 0.447
C18:1ω9 15.41 ± 1.28 15.95 ± 1.47 0.200 16.06± 0.65 15.92 ± 1.13 0.628
C20:1ω9 0.28 ± 0.06 0.28 ± 0.04 0.903 0.30 ± 0.06 0.28 ± 0.05 0.070
C24:1ω9 0.92±0.29 0.80 ± 0.29 0.192 0.77 ± 0.17 0.78 ± 0.25 0.910
Trans fatty acids
C18:2ω6tt 0.16 ± 0.13 0.19 ± 0.13 0.454 0.06 ± 0.05 0.07 ± 0.06 0.695
C18:2ω6ct 0.05 ± 0.03 0.05± 0.03 0.722 0.03 ± 0.04 0.02 ± 0.01 0.578
C18:2ω6tc 0.09 ± 0.03 0.09 ± 0.04 0.969 0.06 ± 0.03 0.06 ± 0.03 0.889
C18:1ω9t 0.47 ± 0.24 0.60 ± 0.31 0.152 0.47 ± 0.15 0.45 ± 0.14 0.542
C16:1ω7t 0.11 ± 0.03 0.11 ± 0.03 0.702 0.15 ± 0.05 0.13 ± 0.04 0.136
Notes: t0, time point for screening visit; t8, time point for end of study visit; p = p-value. Significant differences
in the comparison of baseline to end of study fatty acid compositions in placebo and verum group.
In the placebo group the Omega-3 Index did not change after 8 weeks intervention (4.32 ± 0.35%
to 4.50 ± 0.51%, p = 0.089) (Table 3, Figure 4).
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Figure 4. Omega-3 Indices of 22 participants pre and post treatment with ALA (257 mg/day for
8 weeks (black: pre treatment, grey: post treatment). Mean values pre treatment 4.32 ± 0.35% and post
treatment 4.50 ± 0.51% (p = 0.089).
3.4. Secondary Endpoints, Adverse Events and Laboratory Safety Test
After 8 weeks of intervention, the fat y acid composition in erythrocy es showed sig ificant
changes in verum vs. placebo (Table 3). Both EPA and DHA increased in the verum group.
Docosapentaenoic acid (DPA)-levels increased in both groups. ALA increased only in the placebo
group (mean increase 0.04 ± 0.08%, p = 0.038) (Figure 5), whereas in the verum group ALA levels
decreased (mean decrease −0.02 ± 0.06%, p = 0.141) (Figure 6).
At telephone follow-up at week 4 (t4) in the verum group, one participant was diagnosed with
an influenza infection and three had mild symptoms of a cold. In the placebo group, one had mild
gastrointestinal symptoms with sickness and one had a viral infection with fever, diarrhea a d emesis.
No participant received any antiviral or antibiotic treatment. All documented adverse events were
mild and estimated as not related to the investigational product. In the verum group nine participants
(placebo group five participants) reported that “Weißwurst” and one participant that “Bratwurst”
(one in placebo group) and “Leberkäse” were of no good taste. Palatability (verum 7.0 (4.0; 10.0),
placebo 7.0 (3.0; 10.0); p = 0.922) and tolerability (verum 10.0 (7.0; 10.0), placebo 10.0 (7.0; 10.0);
p = 0.870), both assessed by a visual analog scale, were not different between the two groups.
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Figure 6. Alpha-linolenic acid-levels of 22 participants pre and post treat ent ith EPA and D A
app oxi ately 250 g day) and L 240 g day) for 8 eeks black: p e t eat ent, g ey: post
ea en . ean va ues p e ea en 0.17 0.06 and post treat ent 0.15 0.05% (p = 0.141).
At end-of-study visit (t8) one individual of the placebo group reported mild digestive discomfort.
This adverse event was estimated as possibly related to the investigational product. Two individuals
reported mild symptoms of a cold. From the verum group, no adverse events were reported at t8.
Palatability (verum 7.0 (4.0; 9.0), placebo 7.0 (3.0; 10.0), p = 0.465) and tolerability (verum 10.0 (6.0; 10.0),
placebo 10.0 (7.0; 10.0); p = 0.816) again did not differ between the two groups.
As shown in Table 2, none of the measured clinical and biochemical parameters changed between
the placebo and the verum groups after 8 weeks intervention.
In both groups no individual altered the intake of fatty fish, the current diet or concomitant
medication during the study period. Compliance, assessed by interrogation, was very good in both
groups. All 44 participants finished the trial and no serious adverse events were observed.
3.5. Review of the Literature
As detailed in Table 4, in trials of at least 8 weeks duration, the increase in Omega-3 Index per
100 mg EPA + DHA given per day varied from 0.11 to 0.61 (this trial), with no apparent relation to
chemical form of EPA + DHA. The increase in Omega-3 Index per 100 mg EPA + DHA given for
8 weeks in the sausages studied here was comparable to five months of a fish oil in capsules (Figure 7),
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illustrating the superior bioavailability of the novel source of EPA + DHA studied here. More details
can be found in Figure 7.
Table 4. Comparison of bioavailability of EPA and DHA given in different chemical forms and for
different durations.
Chemical
Form
Baseline Level
EPA + DHA (%)
∆EPA +
DHA (%)
EPA + DHA
(mg/Day)
∆EPA + DHA (%)
/100 mg EPA + DHA Duration n Reference
EE
3.30 * 0.87 3320 0.03 2 weeks 9 [23]
4.18 ± 0.54 1.54 Approximately 250 0.62 8 weeks 22 triOMEG-trial
5.1 * 3.5 3320 0.11 8 weeks 24 [24]
4.46 ± 1.13 2.03 907 0.22 8 weeks 26 [25]4.46 ± 1.13 4.33 3630 0.12 8 weeks 26
6.50 ± 1.46 3.80 3084 0.12 8 weeks 40 [26]
3.50 * 3.20 2500 0.13 60 days 44 [27]
4.6 ± 1.5 3.00 1680 0.18 10 weeks 62 [28]
7.9 ± 3.7 3.4 2520 0.13 12 weeks 11 [29]
8.27 ± 0.77 2.51 1740 0.14 12 weeks 12 [30]
3.91 ± 0.30 0.20 440 0.05 12 weeks 15
[31]3.54 ± 0.26 1.69 1300 0.13 12 weeks 18
3.81 ± 0.23 2.94 2700 0.11 12 weeks 16
4.13 * 3.69 720 0.51 16 weeks 43 [32]
3.7 * 5.4 3360 0.16 16 weeks 30 [33]
3.74 * 7.24 3360 0.22 16 weeks 122 [34]
# 4.84 1680 0.29 6 months 39 [35]
7.6 ± 1.8 4.83 1680 0.29 6 months 39
7.4 ± 1.76 4.82 1680 0.29 6 months 45 [36]
FO
5.2 ± 1.7 4.0 4400 0.09 4 weeks 40 [37]
4.92 * 2.8 1200 0.23 8 weeks 20
[38]6.77 * 6.3 3600 0.18 8 weeks 20
4.04 * 4.14 3360 0.12 8 weeks 21
[39]4.35 * 3.58 3360 0.11 8 weeks 21
4.6 ± 1.6 2.9 1680 0.17 10 weeks 36 [40]
5.74 ± 1.37 5.17 2700 0.19 12 weeks 12 [41]
9.16 ± 1.74 5.08 2520 0.20 12 weeks 7 [42]
5.24 ± 0.7 5.46 2700 0.20 12 weeks 10
[43]4.90 ± 1.8 4.94 2700 0.18 12 weeks 10
5.32 ± 0.74 5.45 2700 0.20 12 weeks 9
[44]4.87 ± 1.83 5.05 2700 0.19 12 weeks 7
4.33 * 1.83 485 0.38 16 weeks 12 [45]
4.7 ± 0.9 3.2 500 0.64 5 months 22 [46]
4.29 ± 0.22 1.90 300 0.63 5 months 23
[47]4.28 ± 0.23 2.54 600 0.42 5 months 214.31 ± 0.22 3.22 900 0.36 5 months 24
4.28 ± 0.22 5.21 1800 0.29 5 months 24
5.5 * 4.46 3360 0.13 6 months 180 [48]
4.7 ± 1.1 4.3 1000 0.43 6 months 20 [49]
3.74 ± 2.02 8.39 2520 0.33 6 months 25 [50]
KO
3.66 ± 0.90 0.31 100 0.31 12 weeks 53
[51]3.56 ± 0.82 0.63 200 0.32 12 weeks 534.00 ± 0.88 1.17 400 0.29 12 weeks 51
3.65 ± 0.70 2.65 800 0.33 12 weeks 58
MO 6.5 * 3.7 1600 0.23 16 weeks 160 [52]
TG 4.37 ± 0.51 2.43 500 0.49 8 weeks 40 [11]
rTG
5.24 * 5.45 2700 0.20 12 weeks 10
[53]4.87 * 5.22 2700 0.19 12 weeks 10
7.11 ± 1.91 6.20 1680 0.37 6 months 34 [54]
7.0 ± 1.9 6.25 1680 0.37 6 months 41 [36]
LEM
3.15 * 0.95 657 0.14 2 weeks 10
[23]3.34 * 1.22 1314 0.09 2 weeks 8
3.14 * 2.18 2628 0.08 2 weeks 10
AG 6.80 ± 1.93 4.30 2697 0.16 8 weeks 39 [26]
Fish 4.02 * 2.15 485 0.44 16 weeks 11 [45]
In all trials listed, samples were analysed with the method used in the present trial (see Methods). Abbreviations:
EE = ethyl-ester, FO = fish oil, KO = krill oil, MO = microalgae oil, TG = triacylglycerides, rTG = re-esterfied
triacylglycerides, LEM = liquid emulsion formulation, AG = acylglycerol; * no SD available; # no baseline EPA + DHA
level available.
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4. Discussion
After daily intake of approximately 250 mg EPA and DHA as ethyl-esters in a variety of sausages
for 8 weeks, the Omega-3 Index increased significantly. There was a large inter-individual variability
in response, although the study population was recruited based on an Omega-3 Index < 5% (Figure 3).
In terms of safety, tolerability and palatability no major problems were noted.
4.1. Screened Individuals
Of 96 individuals screened, only one had an Omega-3 Index in the target range of 8–11% [1,2].
In 106 German athletes of a similar age, we also found only one individual in the target range [55].
The mean Omega-3 Index in the screened individuals was 4.93 ± 1.00%, while it was 4.97 ± 1.19%
in the athletes [55]. In both populations, as in every population so far studied, the Omega-3 Index had
a Gaussian, statistically normal distribution (Figure 1) [55]. Most of the screened individuals in our
study were university students and it has been reported that a higher education level is associated with
a higher Omega-3 Index [56,57]. Therefore, in an unselected German population, an even lower mean
Omega-3 Index might be found. Our finding is consistent with the low intake of fish in individuals
up to age 30 in Germany [58]. The low mean Omega-3 Index puts the individuals screened at risk for
cardiovascular events, issues of impaired complex brain function, and major depression [3,56].
4.2. Choice of Product
The choice of sausages as a vehicle for EPA and DHA may seem odd. However, in Germany,
sausages are part of the everyday diet. Germany has about 1200 different sausages, and some historians
consider eating sausages a defining element for being German [59]. Therefore, selecting sausages as
a vehicle for EPA and DHA in Germany was a logical choice. In our trial, compliance with study
Nutrients 2017, 9, 629 11 of 17
procedures was not an issue. Our trial therefore demonstrates that it is possible to increase the amount
of EPA and DHA in Germans’ everyday diet by using sausages. The increase in the Omega-3 Index
in 8 weeks from mean 4.18 ± 0.54% to 5.72 ± 0.66%, although significant, was not sufficient to bring
the study participants into the target range of 8–11% [3,56]. Therefore, we consider our approach
one option to alleviate the widespread deficit in EPA and DHA, but no solution to it. Moreover,
our approach may not be as viable in other countries or in other populations, like vegetarians.
4.3. Bioavailability of the Investigational Product
In the present study, a daily intake of approximately 250 mg EPA and DHA as ethyl-esters via
sausages for 8 weeks increased the Omega-3 Index from mean 4.18 ± 0.54% to mean 5.72 ± 0.66%
(p < 0.001). Compared to baseline levels, we detected a mean increase of the Omega-3 Index of
1.54 ± 0.75%. This was much higher than the expected 0.6%. Individuals with a low baseline
Omega-3 Index and low body weight experience a greater increase of the Omega-3 Index as a result
of substitution with EPA and DHA than individuals with a high baseline and/or a high body
weight [3,56,60]. Therefore, the low baseline Omega-3 Index, and the fact that we only included
normal weight adults, might partly explain, why we observed a larger response than expected.
Differences in the lipid structure in which EPA and DHA are ingested may influence their
bioavailability and accumulation within lipid pools. Bioavailability of n-3 fatty acids is thought to vary
overall by a factor of two, depending on their chemical form: phospholipid > recombined triglyceride
> triglyceride > free fatty acid > ethyl-ester [12,61–65]. The lower bioavailability of EPA and DHA
from ethyl-esters than from triglycerides is in accord with the demonstration that pancreatic lipase
hydrolyses ethyl-esters to a lesser degree than triglycerides and at a slower rate [63,64,66]. Recently,
we questioned this thought based on the results of a single dose, randomized, double-blind cross-over
trial comparing similar doses of krill oil, krill meal, and fish oil [67]. We found bioavailability of EPA
and DHA in krill oil superior to their bioavailability in krill meal or fish oil, while the bioavailabilities of
EPA and DHA in krill meal or fish oil were comparable. In the krill oil and krill meal studied, EPA and
DHA were bound in phospholipids, while in the fish oil, EPA and DHA were bound in triglycerides.
Therefore, other factors seem to impact bioavailability more than chemical form. Indeed, when
properly emulsified, bioavailability of EPA and DHA ethyl-ester was up to 21-fold better than when
ingested unemulsified in a capsule (as marketed as a drug) [23] Lately, West et al. [68] showed for
healthy individuals that differences in the chemical form of EPA and DHA have no relevant influence
on bioavailability.
The relatively good bioavailability of n-3 fatty acids supplemented as ethyl-esters in various
sausages might be explained by the findings of Nordøy et al., who found an equally good absorption
of n-3 fatty acids from ethyl-esters and triglycerides when given as part of a lipid-rich meal [65].
The absorption of EPA and DHA from ethyl-esters is increased substantially by co-ingestion with
a high-fat meal by enhanced assimilation of ethyl-esters [69].
Most of EPA and DHA are derived from marine sources, and production cannot be increased
easily. New sources of EPA and DHA are currently identified and developed, such as krill, algae, and
genetically modified plants. We consider improving bioavailability of EPA and DHA as important as
developing new sources.
4.4. Variability in Response
As depicted in Figure 3, baseline Omega-3 Index was rather homogeneous in the verum group.
The increase of the Omega-3 Index in response to 250 mg EPA and DHA varied from 0.36–3.07%, which,
based on our findings, would be difficult to explain by issues of compliance. Earlier, we demonstrated
variability of bioavailability of EPA and DHA as a triglyceride in a convenience drink by a factor of
13 inter-individually [20]. In the meantime, however, this has been confirmed by us, and others [47,67].
While predicting a mean dose-response of the Omega-3 Index to supplementation with EPA and DHA
in a population using complicated statistical models is possible, such prediction is basically impossible
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for an individual [20,47,67]. Smoking and physical activity have been reported to correlate inversely
with the Omega-3 Index, and other factors, like genes, also play a role [3,19,56]. We suggest that these
factors might also impact the response of the Omega-3 Index within an eight week study duration.
Larger studies are necessary to clarify what defines the individual response of the Omega-3 Index
in quantitative terms.
4.5. Changes in ALA
All sausages were enriched with ALA, approximately 240 mg in the verum group and 257 mg
in the placebo group. The amount of supplemented omega-3 fatty acids in the investigational
products were not the same in both groups (Table 1). However, ALA (but not EPA or DHA) increased
in the placebo group (and not in the verum group) and showed a large interindividual variability
in response (Figures 5 and 6). DPA increased similarly in both groups (Table 3). Our results support
previous findings that the conversion of ALA into EPA is poor, and into DHA is not of the same
importance in humans. We cannot explain our novel finding that ALA did not increase, when ingested
with EPA and DHA. Although our study is underpowered to investigate all the reported differences
in erythrocyte fatty acid composition, these apparent interactions in omega-3 fatty acid metabolism
suggest further research.
4.6. Clinical Impact
Based on previous epidemiological findings, the increase of the Omega-3 Index in the verum
group should translate into a reduced risk for clinical events like total mortality, cardiovascular
endpoints, major depression, cognitive impairments, and other untoward events [3,6,56,70,71]. It has
been notoriously difficult to translate this reduction of risk into reduction of events in pertinent
intervention trials. We suggest the large inter-individual variability in the response of the Omega-3
Index to increased intake of EPA and DHA as one explanation for the neutral outcome of those
trials. As discussed in more detail elsewhere, we think that aiming for a target range of the Omega-3
Index (e.g., 8–11%) using an individualized dose of EPA and DHA will be a fruitful approach for
intervention trials [72].
4.7. Safety, Tolerability, and Palatability
Placebo-controlled intervention studies showed that side effects of substitution with omega-3
fatty acids are at placebo level [3,56,70–72]. Only one adverse event was reported in our placebo group
(mild digestive discomfort) that was considered as possibly related to the investigational product.
No serious adverse event was reported. The present study was too small to detect rare side effects.
In our small trial, the omega-3 preparation and dose used were safe, of very good tolerability and of
good palatability.
4.8. Strengths and Limitations
Strengths of the study include: (1) a homogenous study population; (2) good palatability and
tolerability of the investigational product; (3) standardized fatty acid analysis using the Omega-3
Index; (4) trial design and reporting conform current standards [73].
Limitations include that the study was (1) a single-centre study; (2) too small to detect rare side
effects; (3) only healthy adults were included; (4) with only eight weeks, relatively short in duration;
(5) the investigational products contained slightly different amounts of supplemented omega-3 fatty
acids; and (6) the study was underpowered for further investigation of changes in erythrocyte fatty
acid composition.
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4.9. Review of the Literature
In our review of intervention trials with EPA + DHA, we compared only trials that used an
identical analytical procedure for the criterion compared. This analytical procedure, the HS-Omega-3
Index, is probably currently the most widely used, and we suggest it to be used in future investigations
in order to make future results comparable to present results, and to facilitate clinical use of fatty
acid analyses.
For the sausages we investigated, we found a mean ∆EPA + DHA in % per 100 mg EPA + DHA
eaten of 0.62%/100 mg, superior to bioavailability of EPA and DHA in other preparations studied so
far (Figure 7, Table 4). For comparison of the trials with different durations and dosages of EPA and
DHA the mean increase of EPA and DHA levels from baseline per 100 mg EPA and DHA substitution
(∆EPA + DHA (%)/100 mg EPA + DHA) was calculated. Clearly, this is not a perfect parameter for
comparison, because levelling-off of the dose response at higher levels has been observed [47], as well
as for other reasons. However, only a parameter like this can make trial results comparable. Notably,
the lowest value of ∆EPA + DHA in % per 100 mg EPA + DHA we found was 0.03 and the highest
0.64. Even among the 10 trials with the same duration (8 weeks), values showed a range between
0.11–0.62%/100 mg (dosages used between 250–3630 mg) (Figure 7). As an explanation, the chemical
form can be neglected, as discussed above, and can also be seen in Table 4 and Figure 7. We suggest
that bioavailability of EPA + DHA depends to some degree on the matrix in which EPA and DHA
are ingested, since EPA and DHA in foods or emulsions seemed to have a higher bioavailability than
EPA and DHA in capsules, and unemulsified (Table 4). However, we cannot exclude many other
mechanisms, including, although not likely, even aspects of catabolism of EPA and DHA. Moreover,
our review of the literature has many limitations, like differences in trial duration and dose, differences
in number, age, gender and comorbidities of participants, and others. However, in light of the fact that
improving bioavailability is a way of improving the Omega-3 Index without increasing production of
EPA and DHA, we suggest intensifying research on this topic.
5. Conclusions
The present trial demonstrated that daily intake of approximately 250 mg EPA and DHA
as ethyl-esters in a variety of sausages for eight weeks increased the Omega-3 Index. The dose
and preparation used were well-tolerated. Corrected for dose and compared with other trials,
the investigated product was very effective in increasing the Omega-3 Index. Clearly, the product
we studied may not be useful for all populations. A large variability in response to EPA and DHA
was observed, which remains to be explained mechanistically. Our findings question the wisdom
of recommending a fixed dose of EPA + DHA, and support individualizing dosing and improving
bioavailability to reach the proposed target range for the Omega-3 Index of 8–11%.
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